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Zhou et al. recently reported findings from a Mendelian
randomization analysis aiming to examine the causal rela-
tionship between metformin use and lung cancer risk.1
This is a topical question because of previously reported
associations between use of metformin, a commonly pre-
scribed drug for the treatment of type 2 diabetes, and lower
cancer risk across several anatomical sites, including lung
cancer.2,3
In lieu of an established drug target of metformin, Zhou
et al. used genetically-proxied measures of growth differenti-
ation factor 15 (GDF15), a cytokine previously reported to
be strongly associated with metformin use,4 to ‘assess the
causal relationship between metformin use and lung cancer
occurrence’. The authors interpreted their findings as indi-
cating no evidence of a causal relationship between these
traits. We have some methodological and interpretative con-
cerns regarding the analyses presented in this paper.
In order to examine the causal effect of metformin on
lung cancer risk using GDF15 as a marker of metformin use,
it is necessary to assume that (i) metformin use affects
GDF15 levels and (ii) any effect of metformin on lung cancer
is entirely mediated through GDF15 levels. Although we be-
lieve the first assumption to have reasonable face validity, we
believe that the second assumption is likely to be violated.
The identification of GDF15 as a potential biomarker
of metformin use was first reported in a cross-sectional
analysis of metformin use and 237 serum biomarkers using
baseline data from 8401 participants enrolled in the
Outcome Reduction with Initial Glargine Intervention
(ORIGIN) trial.4 The large effect size for this association
observed in models adjusted for clinical factors and other
serum biomarkers (Odds ratio of metformin use: 3.94;
95% confidence interval: 3.59–4.33 per standard deviation
increase in GDF15) provides some assurance that this find-
ing is unlikely to be largely driven through residual con-
founding (e.g. due to unmeasured or imprecisely measured
confounders). Though GDF15 appears to be a plausible
mediator of some of the antidiabetic effect of metformin
(e.g. by reducing body weight), reverse causation (i.e.
higher pre-baseline GDF15 levels increasing the likelihood
of subsequent metformin prescription) cannot be ruled out
given emerging evidence to suggest an effect of nutritional
imbalance on circulating GDF15 levels.5,6 At a minimum,
it would have aided the reader in interpreting conclusions
from their analysis if Zhou et al. had more clearly con-
veyed the novelty of the findings reported in the ORIGIN
trial and, thus, the provisional nature of the hypothesized
relationship between metformin use and GDF15.
Even if the assumption that metformin use affects
GDF15 were to hold, we believe that it is incorrect to inter-
pret a Mendelian randomization analysis of GDF15 on lung
cancer risk as being equivalent to assessing ‘causality be-
tween metformin use and lung cancer incidence’, as claimed
by Zhou et al. This is because GDF15 levels represent only
one of several hypothesized mechanistic pathways through
which metformin use may influence subsequent lung cancer
risk.7 For example, metformin has been shown to influence
both (i) tumour metabolism through inhibition of
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mitochondrial complex I and (ii) tumour development
through altered systemic metabolism (e.g. through lowering
blood glucose via reduced hepatic gluconeogenesis, in turn
reducing plasma insulin levels).8,9 Both mechanisms involve
activation of AMP-activated protein kinase (AMPK) by met-
formin, an inhibitor of the mammalian target of the rapamy-
cin (mTOR) pathway, which reduces cell proliferation and
induces cell cycle arrest and apoptosis.7 In addition, it is pos-
sible that GDF15 may simply act as a biomarker of metfor-
min use and may not provide any information on the
mechanism of action of metformin or its health effects. We
therefore believe that the Mendelian randomization analysis
presented by Zhou et al. would more accurately be de-
scribed as an analysis of the effect of GDF15, rather than
metformin use, on lung cancer risk.
Finally, Zhou et al. constructed an instrument to proxy
GDF15 from five genetic variants all of which were in mild
to high linkage disequilibrium (r2 ¼ 0.25–0.80) with at least
one other variant in the instrument. The two sensitivity anal-
yses employed to test for evidence of violations of Mendelian
randomization assumptions either cannot be performed us-
ing correlated variants (weighted median estimation) or are
susceptible to violation of the InSIDE (Instrument Strength
Independent of Direct Effect) assumption (MR-Egger) even if
correlations were considered in the model for this latter
analysis. Effect estimates generated from the weighted me-
dian estimate could be biased either toward or away from
the null, depending on the genetic correlation structure be-
tween individual variants. Consequently, the robustness of
the overall null finding reported by the authors to bias from
negative horizontal pleiotropy (attenuation of the effect esti-
mate toward the null due to the presence of genetic variants
influencing lung cancer through pathways independent to
GDF15) is unclear.
Mendelian randomization remains a potentially power-
ful approach for the discovery, development and repurpos-
ing of pharmacological agents for disease prevention and
treatment.10 However, careful attention must be paid to
both the interpretation and design of such studies in order
to avoid drawing erroneous conclusions.
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